Specialties
Cardiology
Chronic Disease
Dermatology
Emergency
Endocrinology
Gastroenterology
Hematology
Imaging and Intervention
Infectious Disease
Nephrology
Neurology
Obstetrics
Oncology
Ophthalmology
Orthopedic Surgery
Pediatrics
Preclinical
Psychiatry
Public Health
Pulmonology
Rheumatology
Surgery
Urology
Classics™
Wellness
Rewinds
Click for the Rewinds Archive
Write for Us
Writer Application
Submit an Opinion
Subscribe
For Partners
License Content
Submit Press Release
Advertise with Us
Account
Register
Sign-In
Manage Subscriptions
Search
Saturday, October 23, 2021
About
Masthead
License Content
Advertise
Submit Press Release
RSS/Email List
Write for us
Contact us
2 Minute Medicine
Specialties
All
Cardiology
Chronic Disease
Dermatology
Emergency
Endocrinology
Gastroenterology
Hematology
Imaging and Intervention
Infectious Disease
Nephrology
Neurology
Obstetrics
Oncology
Ophthalmology
Orthopedic Surgery
Pediatrics
Preclinical
Psychiatry
Public Health
Pulmonology
Rheumatology
Surgery
Urology
Male sex and older age are independently associated with treatment failure…
Treatment of patent ductus arteriosus in very low birth weight infants…
Lumbar puncture rates appropriately decline in children with simple febrile seizures
Treatment of immune-mediated inflammatory diseases with tumor necrosis factor inhibitors is…
Classics™
Wellness
Rewinds
2 Minute Medicine Rewind October 18, 2021
2 Minute Medicine Rewind, October 12, 2021
2 Minute Medicine Rewind October 4, 2021
2 Minute Medicine Rewind September 27, 2021
2 Minute Medicine Rewind September 20, 2021
Click for the Rewinds Archive
Write for Us
Writer Application
Submit an Opinion
Subscribe
For Partners
License Content
Submit Press Release
Advertise with Us
Account
Register
Sign-In
Manage Subscriptions
Tag: newly diagnosed multiple myeloma
#VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma
Kathleen Lau
-
July 23, 2021
0
Read more
#VisualAbstract TOURMALINE-MM2 trial: Oral ixazomib, lenalidomide, and dexamethasone is a feasible and well-tolerated all-oral regimen in non-transplant, newly diagnosed multiple myeloma
Kathleen Lau
-
April 1, 2021
0
Read more
#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed
Kathleen Lau
-
March 25, 2021
0
Read more
#VisualAbstract Lenalidomide shows improvement in progression-free survival over bortezomib maintenance following autologous stem cell transplantation for multiple myeloma
Kathleen Lau
-
January 28, 2021
0
Read more
#VisualAbstract Administering bortezomib on a weekly basis VS twice weekly basis does not significantly affect progression-free survival (PFS) or overall survival (OS) in Vrd first-line therapy for multiple myeloma...
Kathleen Lau
-
January 1, 2021
0
Read more
